-+ 0.00%
-+ 0.00%
-+ 0.00%

EBOS Group (NZSE:EBO) Stock Seems About Right As Shares Fell 30%

Simply Wall St·11/21/2026 11:10:25
Listen to the news

EBOS Group has seen its share price decline over several years, which puts the spotlight squarely on one issue for investors. Is the current valuation of the stock properly anchored to the earnings the healthcare distributor is producing today?

  • The share price has fallen 29.9% over 3 years. This raises the question of whether the earnings multiple now reflects a reset in expectations or still bakes in a richer outlook.
  • The business relies heavily on its ability to convert healthcare distribution volumes into consistent profit margins. This can influence how much investors are willing to pay for each dollar of earnings.
  • There is a second opinion on EBOS Group worth weighing. See what analysts think EBOS Group's shares could be worth.

For investors, the debate is whether EBOS Group's current share price is justified by the earnings profile the company is delivering right now.

If you are considering whether EBOS Group's current P/E looks high or has adjusted after a 29.9% share price decline over 3 years, it can be helpful to compare it against a wider set of 236 high quality undervalued stocks.

Is EBOS Group Fairly Priced on Earnings?

The P/E ratio works reasonably well for EBOS Group because the business reports positive earnings that give you a clear base for comparison. On this measure, EBOS trades on a P/E of about 16.4x, which sits between the peer group average of roughly 12.3x and the broader healthcare sector at around 18.0x. That places the stock at a premium to similar companies, yet still below the wider industry level.

A fair-value model that blends EBOS Group's growth outlook, profitability and risk suggests a P/E that is close to where the shares currently trade. The present multiple is only slightly above that tailored benchmark, so the market is not assigning an extreme premium or discount on earnings. For an investor, the key consideration is whether the quality and durability of those profits justify paying a bit more than direct peers while still sitting under the sector average. Explore the numbers behind EBOS Group's P/E valuation.

NZSE:EBO P/E Ratio as at Nov 2026
NZSE:EBO P/E Ratio as at Nov 2026

The EBOS Group Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for EBOS Group pick up where the P/E puzzle leaves off and outline the earnings, margin and growth paths that would need to occur for the stock to be worth meaningfully more or less than it is today. Instead of stopping at a single valuation number, these scenarios unpack the specific future that figure relies on so you can monitor how EBOS Group's actual progress aligns with those assumptions over time on the Community page.

One of the top narratives on EBOS Group: 10% undervalued

This Narrative is the bearish analyst Narrative on Simply Wall St, built on the most pessimistic analyst price target and forecasts, not one person's view.

"The main thing that has to go right is that EBOS Group continues to shift its portfolio toward Medical Technology, Animal Care and Retail Pharmacy Brands while lifting returns from the now-complete $360 million distribution centre program and recent acquisitions..."

Discover why this Narrative puts EBOS Group at 10% undervalued.

For EBOS Group, the people behind the numbers still need a closer look

Price and earnings only tell part of the story, because the next question is who is steering EBOS Group and how their pay packets line up with your interests. See who runs EBOS Group and how they are paid.